



LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
RALPH A. LOREN
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
DEBRA J. MILASINIC, Ph.D.
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT
DAVID J. RIKKERS
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
MEGAN E. WILLIAMS, Ph.D.
LISA DIROCCO TYNER

HATHAWAY P. RUSSELL *
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.
MERIDETH C. ARNOLD
DANIELLE L. HERRITT
EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
CHRISTOPHER J. McKENNA

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

PATENT AGENTS
THEODORE R. WEST
JONATHAN M. SPARKS, Ph.D.
ANDRINA WILLIAMS ZINK
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.

* Admitted in TX only
** Admitted in CT only

May 18, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 10/001945
For: *Therapeutic Agents and Methods of Use Thereof for the Modulation of Angiogenesis*
Inventors: Olson, Gary L. et al.
Filed: November 1, 2001
Our Ref. No.: PPI-106CP2

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Supplemental Information Disclosure Statement;
2. PTO Form SB-08;
3. Copies of references cited in PTO Form SB-08 (2);
4. A copy of the International Search Report; and
5. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any other necessary fees due in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, Virginia 22313-1450:

May 18, 2004
Date

Jane E. Remillard, Esq., Registration No. 38,872

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Jane E. Remillard, Esq.
Registration No. 38,872
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Olson, Gary L. *et al.*

Serial No.: 10/001945

Filed: November 1, 2001

For: *Therapeutic Agents and Methods of Use
Thereof for the Modulation of Angiogenesis*

Attorney Docket No.: PPI-106CP2

Group Art Unit: 1654

Examiner: Not Yet Assigned

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

By:

Jane E. Remillard, Esq.
Reg. No. 38,872
Attorney for Applicants

May 18, 2004
Date of Signature and of Mail Deposit

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Dear Sir:

Applicants and their Attorney have become aware of the following publications and information, cited in an International Search Report mailed November 13, 2003 during the prosecution of PCT/US03/13623 which corresponds to the above-referenced application. In accordance with 37 CFR §1.97, Applicants hereby submit these publications for the Examiner's consideration. These publications are cited on the enclosed PTO Form SB-08, and a copy of the Report and each publication cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(c)(2) and §1.17(p), please charge the \$180.00 submission fee to our Deposit Order Account No. 12-0080. Please charge any necessary additional fees or credit any overpayments to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP



Jane E. Remillard, Esq.
Registration No. 38,872
Attorney for Applicants

28 State Street
Boston, MA 02109
(617) 227-7400

Date: May 18, 2004

JER/MCL/JMS/alf
Enclosures



MAY 20 2004

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/001945
				Filing Date	November 1, 2001
				First Named Inventor	Olson, Gary L.
				Art Unit	1654
				Examiner Name	Not Yet Assigned
Sheet	1	of		Attorney Docket Number	PPI-106CP2

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁵
Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.⁶

NON-PATENT LITERATURE DOCUMENTS

NON-PATENT WORKS DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		T ²
Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.